<DOC>
	<DOCNO>NCT02234869</DOCNO>
	<brief_summary>The primary objective study evaluate , participant RMS , safety tolerability ( defined frequency adverse event [ AEs ] flu-like symptom [ FLS ; chill , pyrexia , myalgia , asthenia ] , injection site reaction [ ISRs ] , injection site reaction pain [ ISR-P ] ) 6 month treatment ( active comparator period ) BIIB017 125 μg subcutaneously ( SC ) every 2 week versus standard-of-care SC interferon-beta ( IFN-β ) therapy . Secondary objective study assess follow measure first ( 6-month ) period study participant treat BIIB017 versus standard-of-care SC IFN-β therapy : patient-reported treatment satisfaction use follow patient-reported outcome measure ( PROMs ) : Treatment Satisfaction Questionnaire Medication ( TSQM-9 ) , Adapted MS Treatment Concerns Questionnaire ( MSTCQ ) , Adapted MSTCQ Side Effects Score , Pain use visual analog scale ( VAS ) diary McGill Pain Questionnaire Short Form ( SF-MPQ ) , treatment ' impact RMS use follow PROMs : Multiple Sclerosis Impact Scale ( MSIS-29 ) , Modified Fatigue Impact Scale-5 Item ( MFIS-5 ) , EuroQol Group 5-Dimension 3-Level Version ( EQ-5D-3L ) , Health-Related Productivity Questionnaire ( HRPQ ) , Beck Depression Inventory , second edition ( BDI-II ) , participant adherence study treatment , clinical status measure Expanded Disability Status Scale ( EDSS ) relapse activity , safety tolerability study treatment change standard-of-care SC IFN-β therapy immunogenicity profile participant change standard-of-care SC IFN-β BIIB017 .</brief_summary>
	<brief_title>Transition Peginterferon Beta-1a ( BIIB017 ) From Subcutaneous Interferon Therapy</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-beta</mesh_term>
	<mesh_term>Interferon beta-1a</mesh_term>
	<criteria>Key Must confirm diagnosis Relapsing Multiple Sclerosis ( RMS ) , define McDonald criterion . An Expanded Disability Status Scale ( EDSS ) score 0 5.0 . On continual treatment ≥6 month single standardofcare subcutaneous ( SC ) interferon beta ( IFNβ ) therapy , include IFN β1b 0.25 mg SC every day IFN β1a 44 μg SC 3 time weekly , clinical perspective able continue therapy ( i.e. , significant untoward event attribute IFN therapy would preclude continuation exist IFN therapy ) . A candidate change BIIB017 therapy ( candidacy therapy change determine treat physician ; however , recommend exclude patient high disease activity candidate escalation therapy accord local guideline ) . Patients randomize current standardofcare IFNβ therapy first 6 month study must willing receive treatment via formulation provide study ( i.e. , Rebif 44 μg prefilled syringe Betaferon/Betaseron 0.25 mg singleuse vial lyophilize powder accompany prefilled singleuse diluent syringe ) . Key Primary progressive , secondary progressive , progressive relapse MS. History inadequate response SC IFN therapy ( determined treat physician ) . History severe allergic anaphylactic reaction know hypersensitivity study drug excipients . Known allergy component BIIB017 formulation . History clinically significant ( determined Investigator ) cardiac , endocrinologic , hematologic , hepatic , immunologic , metabolic , urologic , pulmonary , neurologic , dermatologic , psychiatric , renal , major disease would preclude participation clinical study . History hypersensitivity intolerance acetaminophen , ibuprofen , naproxen , aspirin would preclude use least one study . An MS relapse occur within 50 day prior randomization and/or lack stabilization previous relapse prior randomization . Any previous treatment BIIB017 . Treatment agent MS . NOTE : Other protocol define Inclusion/Exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2014</verification_date>
	<keyword>Peginterferon Beta-1a</keyword>
	<keyword>Relapsing Multiple Sclerosis</keyword>
	<keyword>RMS</keyword>
	<keyword>flu-like symptom</keyword>
</DOC>